IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

Blood Adv · 2026 · PMC13094439 · PMID 41701976

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

approaching significanceP = .063so close (0.05 < p ≤ 0.1)

In contrast, del(1p32) alone had no impact on PFS, and in combination with IgH translocations was approaching significance ( Figure 3 E; P = .063), although we note low numbers of patients with this combination in the current cohort.

also in 1,073 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.